CENTESSA PHARMACEUTICALS PLC - AMERICAN DEPOSITARY

13,61

02-мая-25 16:45:00

15 мин. задержка

Акции

+0,11

+0,81%

Сегодняшний диапазон

13,49 - 14,39

ISIN

N/A

Источник

NASDAQ

Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024

24 мар 2025 07:00:49 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

06 мар 2025 16:14:40 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

28 янв 2025 08:00:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

08 янв 2025 07:05:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

12 ноя 2024 07:00:15 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

04 ноя 2024 07:30:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

26 сен 2024 06:00:31 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

12 сен 2024 22:34:37 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

11 сен 2024 16:04:47 Источник Nasdaq GlobeNewswire
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

10 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

27 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

21 авг 2024 08:00:45 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

13 авг 2024 07:00:41 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer

10 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

21 май 2024 08:45:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024

13 май 2024 16:10:29 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares

23 апр 2024 21:36:40 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares

23 апр 2024 16:17:37 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

22 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023

28 мар 2024 16:28:47 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.